Skip to main content
. Author manuscript; available in PMC: 2025 Mar 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2024 Mar 1;95(3):297–303. doi: 10.1097/QAI.0000000000003358

Table 5:

Percent of participants with sustained plasma HIV RNA suppression by genotype.

Gene Genetic variant % suppressed
ABCG2 C/C 16/43 (37.21%)
A/A or C/A 2/10 (20.00%)
NR1I2 C/C 7/20 (35.00%)
T/T or C/T 11/33 (33.33%)
UGT1A1 (Model 1) Normal 11/36 (30.56%)
Intermediate 5/13 (38.46%)
Poor 2/4 (50.00%)
UGT1A1 (Model 2) Normal/Intermediate 16/49 (32.65%)
Poor 2/4 (50.00%)